Quick Answer
GRI Bio, Inc. reported R&D Expense of $6.82 million for fiscal year 2025.
GRI Bio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.82M | +81.0% |
| 2024 | $3.77M | +16.6% |
| 2023 | $3.23M | +1235.5% |
| 2022 | $242.0K | -95.3% |
| 2021 | $5.19M | +39.9% |
| 2020 | $3.71M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.77M | +57.2% | -5.9% |
| June 30, 2025 | $1.88M | +114.3% | +14.6% |
| March 31, 2025 | $1.64M | +75.8% | +45.8% |
| September 30, 2024 | $1.12M | -5.4% | +28.3% |
| June 30, 2024 | $877.0K | -0.3% | -6.0% |
| March 31, 2024 | $933.0K | +704.3% | -21.5% |
| September 30, 2023 | $1.19M | +1787.3% | +35.1% |
| June 30, 2023 | $880.0K | +1391.5% | +658.6% |
- GRI Bio, Inc. showed an increase of +81.0% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, GRI Bio, Inc.’s r&d expense has grown by 83.9% (from $3.71 million to $6.82 million).
- The most recent figure is from GRI Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on January 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: